Lupin Limited · NSE:LUPIN
Lupin — Q1 FY23 Earnings Presentation
14 slides from Lupin's earnings presentation, Aug 4, 2022
Slide 1: Cover letter to stock exchanges: Investor Presentation Q1 FY23
.1.... ~ LUPIN August 4, 2022 BSE Limited Department of Corporate Services, P. J. Towers, Dalal Street, MUMBAI - 400 001. ~nal Stock Exchange ot India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai~ 400 051. Dear Sir /Madam, Sub: Investor Presentation Ql FY23 Pursuant to Regulat
Slide 2: Investor Presentation Q1 FY23
Investor Presentation Q1 FY23 August 4, 2022
Slide 3: Safe Harbor Statement
Safe Harbor Statement Materials and information provided during this presentation may contain forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ
Slide 4: Lupin Today
Lupin Today Financial Metrics Globally Major Markets Market Cap (1,2) US$ 3.6 bn 10th 6th 3rd 6th Largest Generic Largest Indian Largest in India Pharma Revenue (FY22)(3) US$ 2.2 bn company Pharma the US Market Rank5 (by sales4) (by global sales4) (by prescriptions5) EBITDA (FY22)(3) US$ 311 mn Neth
Slide 5: Strategic Vision Update: A Global Pharma Company Focused on our Core Growth Platforms
Strategic Vision Update: A Global Pharma Company Focused on our Core Growth Platforms India Complex Gx Global Developed Gx Region Platforms Market Footprint Achieving substantially Substantial and scaled Operational efficiency above market growth product platforms from Global presence Organic and in
Slide 6: Financial Results Review
Financial Results Review
Slide 7: Q1 FY23 Snapshot
Q1 FY23 Snapshot Mr. Nilesh.D.Gupta Important developments Managing Director Commercial Lupin Limited Sales (In INR mn and %) • Rapid Expansion of Lupin Diagnostic In India: North America, ➢ Launches its First Regional Reference India, 14,920, 41% 10,104, 28% Laboratory in Patna Total “Our numbers a
Slide 8: P&L Highlights- Q1 FY23
P&L Highlights- Q1 FY23 QoQ YoY Amount in INR mn Q1FY23 % of Sales Q4FY22 % of Sales Q1FY22 % of Sales Growth Growth Sales 36,040 100.0% 38,645 100.0% -6.7% 42,374 100.0% -14.9% Other operating income 1,399 3.9% 185 0.5% 656.1% 328 0.8% 326.5% Total revenue 37,438 103.9% 38,830 100.5% -3.6% 42,702 1
Slide 9: India Business Update
Q1FY23 41.4% YoY QoQ % of Sales India Business Update -8.8% 10.4% India Quarterly Sales (INR mn) Lupin continues to outpace industry growth in Chronic 16,362 15,435India Quarterly Sales (INR mn) 14,920 CAGR MAT JUN’18 – ’22 Lupin Rank1 14,733 13,511 Therapy Market Lupin MAT JUN’18 MAT JUN’22 Acute 1
Slide 10: North America: US Generics
Q1FY23 28% YoY QoQ % of North America -24.2% -28.7% US Generics: An established leader Managing our transition to Complex Generics US quarterly sales ($ mn) 44 23.2% 113 202 200 184 181 Number of Albuterol Gx Number of 172 products Market share2 Products Top 3 by 150 Market leader1 Market Share1 121
Slide 11: Other Markets
Other Markets • Germany: EUR 9.2 mn sales in Q1 FY23 versus EUR 7.4 mn in Q1 FY22 EU5 • Developed Namuscla®, Tempil® and various sexual health portfolio products contributed to double-digit EMEA YoY growth in revenues in Q1 FY23 • 6th largest generics player1; Market leader in CVS space South Africa
Slide 12: Key Financial Metrics
Key Financial Metrics R&D (INR mn) Capex (INR mn) 3,737 2,787 3,546 3,442 3,478 1,451 1,577 1,613 3,300 1,057 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1 FY23 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1 FY23 Net debt/ Equity R&D (% of Sales) 9.6% 0.21 0.18 8.9% 0.16 8.8% 8.7% 8.2% (0.02) (0.01) Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q1
Slide 13: Lupin – Awards and Accolades
Lupin – Awards and Accolades • Vinita Gupta, named among India’s 20 Most Influential Women in Healthcare by BW Healthcare World • Rajendra Chunodkar named among the Game Changers in Manufacturing by Fortune India • Lupin wins the prestigious ATD (Association of Talent Development) BEST Award • Lupin
Slide 14: THANK YOU
THANK YOU Registered Office Lupin Limited, 3rd Floor, Kalpataru Inspire, Off. Western Expressway Highway, Santacruz (East), Mumbai 400 055, India. Phone: +91 22 6640 2323 | Fax: +91 22 6640 2051 | www.lupin.com lupin LupinGlobal LupinWorld Lupin Global